These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35668346)

  • 1. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
    Tanneau L; Karlsson MO; Diacon AH; Shenje J; De Los Rios J; Wiesner L; Upton CM; Dooley KE; Maartens G; Svensson EM
    Clin Pharmacokinet; 2022 Aug; 61(8):1177-1185. PubMed ID: 35668346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
    Sasaki T; Svensson EM; Wang X; Wang Y; Hafkin J; Karlsson MO; Mallikaarjun S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0160821. PubMed ID: 34843388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
    Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
    Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis.
    Ahmed SH; Haider H; Moeed A; Mahmood A; Shivani N; Shuja SH; Hayat J; Jamil B; Fatima R
    Indian J Tuberc; 2024 Jan; 71(1):79-88. PubMed ID: 38296395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
    Alghamdi WA; Al-Shaer MH; Kipiani M; Barbakadze K; Mikiashvili L; Kempker RR; Peloquin CA
    J Antimicrob Chemother; 2021 Mar; 76(4):1019-1024. PubMed ID: 33378452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
    Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R
    Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid.
    Chen Q; Huang T; Zou L; Tang X; Shi Z; Wang X; Wu H; Sun J; Lu X; Liang L; Jiang L; Liu D; Tang S; Wu G; He W
    Sci Rep; 2024 Jul; 14(1):17347. PubMed ID: 39069547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
    Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
    Wang X; Mallikaarjun S; Gibiansky E
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Mallikaarjun S; Wells C; Petersen C; Paccaly A; Shoaf SE; Patil S; Geiter L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5976-85. PubMed ID: 27458223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
    Tanneau L; Karlsson MO; Rosenkranz SL; Cramer YS; Shenje J; Upton CM; Morganroth J; Diacon AH; Maartens G; Dooley KE; Svensson EM
    Clin Pharmacol Ther; 2022 Oct; 112(4):873-881. PubMed ID: 35687528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.